{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:08:03Z","timestamp":1783181283864,"version":"3.54.6"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F2G Ltd and Shionogi B.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite notable progress, the management of invasive aspergillosis (IA) remains challenging and treatment failures are common. The final patient outcome is subject to multiple factors including the host (the severity of the underlying conditions), the fungus (the virulence and susceptibility pattern of the Aspergillus species involved), and the therapy (the timing related to severity of infection and choice of therapy\u2014dose, efficacy, cidal versus static, toxicity and interaction). Consequently, assessment of failure is complex yet crucial in order to ensure appropriate management.<\/jats:p>\n               <jats:p>Refractoriness in absence of drug resistance may reflect severity of the underlying disease\/infection at the time of initiation of therapy prolonging time to response. It may also reflect a suboptimal antifungal drug exposure due to poor compliance, inappropriate dosing or increased drug metabolism, or it may reflect \u2018pseudo\u2019 failure due to worsening of imaging due to recovery of neutrophils. Refractoriness may also be related to inherent drug resistance in various Aspergillus species or acquired resistance in a normally susceptible species. The latter scenario is mostly encountered in A. fumigatus, where azole resistance is increasing and includes azole-naive patients due to resistance related to azole fungicide use in agriculture and horticulture. Although diagnostics and resistance detection have been greatly improved, the time to resistance reporting is often still suboptimal, which calls for close assessment and potentially management changes even before the susceptibility is known.<\/jats:p>\n               <jats:p>In this article we address the various definitions and approaches to assessment and management of clinical refractoriness\/failure in the setting of proven and probable IA.<\/jats:p>","DOI":"10.1093\/jac\/dkaf003","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:29:41Z","timestamp":1741969781000},"page":"i9-i16","source":"Crossref","is-referenced-by-count":5,"title":["Refractory versus resistant invasive aspergillosis"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":false,"given":"Maiken Cavling","family":"Arendrup","sequence":"first","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut , Building 45, room 123, Artillerivej 5, DK-2300 Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Microbiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"Department of Haematology, Henri Mondor Teaching Hospital, Assistance Publique-H\u00f4pitaux de Paris, and Universit\u00e9 Paris-Est-Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025031416293353000_dkaf003-B1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw444","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"2025031416293353000_dkaf003-B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025031416293353000_dkaf003-B6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2025031416293353000_dkaf003-B7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2025031416293353000_dkaf003-B8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis\u202f: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2025031416293353000_dkaf003-B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025031416293353000_dkaf003-B10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2214\/AJR.05.0513","article-title":"Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome","volume":"187","author":"Brodoefel","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"2025031416293353000_dkaf003-B13","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s00330-016-4717-4","article-title":"Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis","volume":"27","author":"Vehreschild","year":"2017","journal-title":"Eur Radiol"},{"key":"2025031416293353000_dkaf003-B14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025031416293353000_dkaf003-B15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12281-018-0322-0","article-title":"Diagnosing invasive mold infections: what is next","volume":"12","author":"Mercier","year":"2018","journal-title":"Curr Fungal Infect Rep"},{"key":"2025031416293353000_dkaf003-B16","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.ejrad.2009.05.058","article-title":"Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials","volume":"74","author":"Caillot","year":"2010","journal-title":"Eur J Radiol"},{"key":"2025031416293353000_dkaf003-B17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/cid\/ciz1195","article-title":"How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions","volume":"71","author":"Fern\u00e1ndez-Cruz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy Series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025031416293353000_dkaf003-B19","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/jac\/dkac301","article-title":"Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis","volume":"77","author":"Colombo","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/jac\/dkab317","article-title":"When to change treatment of acute invasive aspergillosis: an expert viewpoint","volume":"77","author":"Slavin","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection\u2014position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2025031416293353000_dkaf003-B22","volume-title":"Atlas of Clinical Fungi. The Ultimate Benchtool for Diagnostics","author":"de Hoog","year":"2020","edition":"4th edn"},{"key":"2025031416293353000_dkaf003-B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.riam.2022.04.002","article-title":"Aspergillosis by cryptic Aspergillus species: a case series and review of the literature","volume":"39","author":"Fernandez-Pittol","year":"2022","journal-title":"Rev Iberoam Micol"},{"key":"2025031416293353000_dkaf003-B24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/myc.13348","article-title":"Invasive aspergillosis due to Aspergillus cryptic species: a prospective multicentre study","volume":"64","author":"Imbert","year":"2021","journal-title":"Mycoses"},{"key":"2025031416293353000_dkaf003-B25","doi-asserted-by":"publisher","first-page":"e01374-20","DOI":"10.1128\/AAC.01374-20","article-title":"Multicentric analysis of the species distribution and antifungal susceptibility of cryptic isolates from Aspergillus section fumigati","volume":"64","author":"Imbert","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B26","doi-asserted-by":"publisher","first-page":"e01527-20","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2025031416293353000_dkaf003-B28","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B29","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1128\/AAC.41.6.1364","article-title":"Itraconazole resistance in Aspergillus fumigatus","volume":"41","author":"Denning","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2025031416293353000_dkaf003-B31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jac\/40.3.401","article-title":"Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection","volume":"40","author":"Denning","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/infdis\/jis442","article-title":"In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration","volume":"206","author":"Arendrup","year":"2012","journal-title":"J Infect Dis"},{"key":"2025031416293353000_dkaf003-B33","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fmicb.2020.01850","article-title":"Azole-resistant Aspergillus fumigatus among Danish cystic fibrosis patients: increasing prevalence and dominance of TR34\/L98H","volume":"11","author":"Risum","year":"2020","journal-title":"Front Microbiol"},{"key":"2025031416293353000_dkaf003-B34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N Engl J Med"},{"key":"2025031416293353000_dkaf003-B35","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3390\/microorganisms9122439","article-title":"Selection and amplification of fungicide resistance in Aspergillus fumigatus in relation to DMI fungicide use in agronomic settings: hotspots versus coldspots","volume":"9","author":"Doughty","year":"2021","journal-title":"Microorganisms"},{"key":"2025031416293353000_dkaf003-B36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3201\/eid3008.240096","article-title":"Environmental hot spots and resistance-associated application practices for azole-resistant Aspergillus fumigatus, Denmark, 2020\u20132023","volume":"30","author":"Arendrup","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2025031416293353000_dkaf003-B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/myc.13426","article-title":"Azole resistance in Aspergillus fumigatus. The first 2-year\u2019s data from the Danish National Surveillance Study, 2018-2020","volume":"65","author":"Risum","year":"2022","journal-title":"Mycoses"},{"key":"2025031416293353000_dkaf003-B38","doi-asserted-by":"publisher","first-page":"e0206121","DOI":"10.1128\/aem.02061-21","article-title":"Citizen-science surveillance of triazole-resistant Aspergillus fumigatus in UK residential garden soils","volume":"88","author":"Shelton","year":"2022","journal-title":"Appl Environ Microbiol"},{"key":"2025031416293353000_dkaf003-B39","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/jac\/dkac161","article-title":"Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications","volume":"77","author":"Rogers","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jof7030164","article-title":"Genetic and phenotypic characterization of in-host developed azole-resistant Aspergillus flavus isolates","volume":"7","author":"Buil","year":"2021","journal-title":"J Fungi"},{"key":"2025031416293353000_dkaf003-B41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ijantimicag.2008.06.018","article-title":"Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus","volume":"32","author":"Krishnan-Natesan","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2025031416293353000_dkaf003-B42","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1128\/AAC.00637-15","article-title":"A novel Y319H substitution in CYP51C associated with azole resistance in Aspergillus flavus","volume":"59","author":"Paul","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes11101217","article-title":"Point mutations in the 14-\u03b1 sterol demethylase Cyp51A or Cyp51C could contribute to azole resistance in Aspergillus flavus","volume":"11","author":"Lucio","year":"2020","journal-title":"Genes (Basel)"},{"key":"2025031416293353000_dkaf003-B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00865-19","article-title":"Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in Spain","volume":"63","author":"Rivero-Menendez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01928-17","article-title":"Investigation of multiple resistance mechanisms in voriconazole-resistant Aspergillus flavus clinical isolates from a chest hospital surveillance in Delhi, India","volume":"62","author":"Sharma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01610-18","article-title":"Microsatellite typing and resistance mechanism analysis of voriconazole-resistant Aspergillus flavus isolates in South Korean hospitals","volume":"63","author":"Choi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01216-18","article-title":"Contributions of yap1 mutation and subsequent atrF upregulation to voriconazole resistance in Aspergillus flavus","volume":"62","author":"Ukai","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/pathogens13010012","article-title":"Species distribution and antifungal susceptibilities of Aspergillus section terrei isolates in clinical samples from the United States and description of Aspergillus pseudoalabamensis sp. nov","volume":"12","author":"Ca\u00f1ete-Gibas","year":"2023","journal-title":"Pathogens"},{"key":"2025031416293353000_dkaf003-B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9030539","article-title":"The environmental spread of Aspergillus terreus in Tyrol, Austria","volume":"9","author":"Dietl","year":"2021","journal-title":"Microorganisms"},{"key":"2025031416293353000_dkaf003-B50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B51","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025031416293353000_dkaf003-B52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B53","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B54","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B55","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"2025031416293353000_dkaf003-B56","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2025031416293353000_dkaf003-B58","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031416293353000_dkaf003-B59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025031416293353000_dkaf003-B60","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1093\/infdis\/jiad067","article-title":"Radiotracer development for fungal-specific imaging: past, present, and future","volume":"228","author":"Lai","year":"2023","journal-title":"J Infect Dis"},{"key":"2025031416293353000_dkaf003-B61","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/QCO.0000000000000937","article-title":"Radiology-based diagnosis of fungal pulmonary infections in high-risk hematology patients: are we making progress?","volume":"36","author":"Lewis","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"2025031416293353000_dkaf003-B62","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/bmt.2011.246","article-title":"ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia","volume":"47","author":"Arendrup","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2025031416293353000_dkaf003-B63","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cmi.2019.11.019","article-title":"High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum","volume":"26","author":"Vergidis","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2025031416293353000_dkaf003-B64","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/mmy\/myz004","article-title":"Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of Aspergillus by MALDI-TOF","volume":"57","author":"Imbert","year":"2019","journal-title":"Med Mycol"},{"key":"2025031416293353000_dkaf003-B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/spectrum.02626-21","article-title":"Comparison of the performance of two galactomannan detection tests: platelia Aspergillus Ag and Aspergillus galactomannan Ag virclia monotest","volume":"10","author":"Calero","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025031416293353000_dkaf003-B66","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/mmy\/myz079","article-title":"Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study","volume":"58","author":"Mercier","year":"2019","journal-title":"Med Mycol"},{"key":"2025031416293353000_dkaf003-B67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025031416293353000_dkaf003-B68","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.drup.2022.100885","article-title":"Dual use of antifungals in medicine and agriculture: how do we help prevent resistance developing in human pathogens?","volume":"65","author":"Verweij","year":"2022","journal-title":"Drug Resist Updat"},{"key":"2025031416293353000_dkaf003-B69","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/22221751.2022.2034485","article-title":"Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance","volume":"11","author":"Buil","year":"2022","journal-title":"Emerg Microbes Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_1\/i9\/62415770\/dkaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_1\/i9\/62415770\/dkaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:29:47Z","timestamp":1741969787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/Supplement_1\/i9\/8078711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":69,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf003","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}